Abstract
Correcting aberrant folds that develop during protein folding disease states is now an active research endeavor that is attracting increasing attention from both academic and industrial circles. One particular approach focuses on developing or identifying small molecule correctors or pharmacological chaperones that specifically stabilize the native fold. Unfortunately, the limited screening platforms available to rapidly identify or validate potential drug candidates are usually inadequate or slow because the folding disease proteins in question are often transiently folded and/or aggregationprone, complicating and/or interfering with the assay outcomes. In this review, we outline and discuss the numerous platform options currently being employed to identify small molecule therapeutics for folding diseases. Finally, we describe a new stability screening approach that is broad based and is easily applicable toward a very large number of both common and rare protein folding diseases. The label free screening method described herein couples the promiscuity of the GroEL binding to transient aggregation-prone hydrophobic folds with surface plasmon resonance enabling one to rapidly identify potential small molecule pharmacological chaperones.
Keywords: Protein misfolding, missense mutations, pharmacological chaperones, GroEL chaperonin, Surface Plasmon Resonance
Current Topics in Medicinal Chemistry
Title:On the Design of Broad Based Screening Assays to Identify Potential Pharmacological Chaperones of Protein Misfolding Diseases
Volume: 12 Issue: 22
Author(s): Subhashchandra Naik, Na Zhang, Phillip Gao and Mark T. Fisher
Affiliation:
Keywords: Protein misfolding, missense mutations, pharmacological chaperones, GroEL chaperonin, Surface Plasmon Resonance
Abstract: Correcting aberrant folds that develop during protein folding disease states is now an active research endeavor that is attracting increasing attention from both academic and industrial circles. One particular approach focuses on developing or identifying small molecule correctors or pharmacological chaperones that specifically stabilize the native fold. Unfortunately, the limited screening platforms available to rapidly identify or validate potential drug candidates are usually inadequate or slow because the folding disease proteins in question are often transiently folded and/or aggregationprone, complicating and/or interfering with the assay outcomes. In this review, we outline and discuss the numerous platform options currently being employed to identify small molecule therapeutics for folding diseases. Finally, we describe a new stability screening approach that is broad based and is easily applicable toward a very large number of both common and rare protein folding diseases. The label free screening method described herein couples the promiscuity of the GroEL binding to transient aggregation-prone hydrophobic folds with surface plasmon resonance enabling one to rapidly identify potential small molecule pharmacological chaperones.
Export Options
About this article
Cite this article as:
Naik Subhashchandra, Zhang Na, Gao Phillip and T. Fisher Mark, On the Design of Broad Based Screening Assays to Identify Potential Pharmacological Chaperones of Protein Misfolding Diseases, Current Topics in Medicinal Chemistry 2012; 12 (22) . https://dx.doi.org/10.2174/1568026611212220006
DOI https://dx.doi.org/10.2174/1568026611212220006 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Expression and Function of the Endocannabinoid System in Glial Cells
Current Pharmaceutical Design Anti-Inflammatory Drugs in the Treatment of Neurodegenerative Diseases: Current State
Current Pharmaceutical Design Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets Alkaloids from Cyanobacteria with Diverse Powerful Bioactivities
Mini-Reviews in Medicinal Chemistry AZT: An Old Drug with New Perspectives
Current Clinical Pharmacology A Role for TGF-β Signaling in Neurodegeneration: Evidence from Genetically Engineered Models
Current Alzheimer Research Subject Index to Volume 4
Current Medicinal Chemistry - Central Nervous System Agents Towards Environmental Construct Validity in Animal Models of CNS Disorders: Optimizing Translation of Preclinical Studies
CNS & Neurological Disorders - Drug Targets An Enriched Population of CD45, CD34 and CD117 Stem Cells in Human Umbilical Cord Blood for Potential Therapeutic Regenerative Strategies
Current Neurovascular Research Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry Endothelium and Oxidative Stress: The Pandora's Box of Cerebral (and Non-Only) Small Vessel Disease?
Current Molecular Medicine Meet Our Associate Editor:
Current Molecular Medicine AMPK in Neurodegenerative Diseases: Implications and Therapeutic Perspectives
Current Drug Targets Brain Cancer-Activated Microglia: A Potential Role for Sphingolipids
Current Medicinal Chemistry The Biology of Neurotrophins, Signalling Pathways, and Functional Peptide Mimetics of Neurotrophins and their Receptors
CNS & Neurological Disorders - Drug Targets Molecular Insights into Mechanisms of the Cell Death Program:Role in the Progression of Neurodegenerative Disorders
Current Alzheimer Research Targeting Exocytosis: Ins and Outs of the Modulation of Quantal Dopamine Release
CNS & Neurological Disorders - Drug Targets Chelating Agents for Metal Intoxication
Current Medicinal Chemistry Editorial
Current Molecular Medicine